Enovis Corp Cash Flow Conversion Efficiency
Enovis Corp cash flow conversion efficiency. Based on the latest financial reports, Enovis Corp (ENOV) has a cash flow conversion efficiency ratio of 0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($75.03 Million) by net assets ($1.48 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Enovis Corp (2005–2025)
Cash flow conversion efficiency of Enovis Corp from 2005 to 2025. This chart illustrates how Enovis Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ENOV stock price for real-time trading data and today's change.
Enovis Corp Cash Flow Conversion Ratio Explained
Enovis Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Enovis Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enovis Corp ranked by their cash flow conversion efficiency. Also see how much is Enovis Corp worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lemon Tree Hotels Limited
NSE:LEMONTREE
|
0.113x |
|
Fermi Inc.
NASDAQ:FRMI
|
-0.047x |
|
Glenveagh Properties PLC
IR:GVR
|
0.096x |
|
China Reform Health Management and Services Group Co Ltd
SHE:000503
|
-0.066x |
|
Ningbo Fujia Industrial Co Ltd
SHG:603219
|
0.020x |
|
Ventyx Biosciences Inc
NASDAQ:VTYX
|
-0.091x |
|
International General Insurance Holdings Ltd
NASDAQ:IGIC
|
0.162x |
|
Wuxi Dk Electronic Materials Co Ltd
SHE:300842
|
0.282x |
Annual Cash Flow Conversion Efficiency for Enovis Corp (2005–2025)
The table below shows the annual cash flow conversion efficiency of Enovis Corp from 2005 to 2025. Review ENOV cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.49 Billion | $217.29 Million | 0.146x | +229.05% |
| 2024-12-31 | $2.56 Billion | $113.50 Million | 0.044x | +12.17% |
| 2023-12-31 | $3.42 Billion | $134.99 Million | 0.039x | +343.71% |
| 2022-12-31 | $3.45 Billion | $-55.86 Million | -0.016x | -121.20% |
| 2021-12-31 | $4.66 Billion | $356.10 Million | 0.076x | -9.22% |
| 2020-12-31 | $3.59 Billion | $301.94 Million | 0.084x | +124.26% |
| 2019-12-31 | $3.49 Billion | $130.95 Million | 0.038x | -42.36% |
| 2018-12-31 | $3.48 Billion | $226.37 Million | 0.065x | +10.92% |
| 2017-12-31 | $3.73 Billion | $218.77 Million | 0.059x | -26.49% |
| 2016-12-31 | $3.09 Billion | $246.97 Million | 0.080x | -14.42% |
| 2015-12-31 | $3.26 Billion | $303.81 Million | 0.093x | -18.92% |
| 2014-12-31 | $3.35 Billion | $385.76 Million | 0.115x | -12.91% |
| 2013-12-31 | $2.74 Billion | $362.17 Million | 0.132x | +73.40% |
| 2012-12-31 | $2.16 Billion | $164.30 Million | 0.076x | -74.77% |
| 2011-12-31 | $189.28 Million | $57.15 Million | 0.302x | +5.44% |
| 2010-12-31 | $216.37 Million | $61.97 Million | 0.286x | +48.73% |
| 2009-12-31 | $198.83 Million | $38.29 Million | 0.193x | +202.00% |
| 2008-12-31 | $166.93 Million | $-31.51 Million | -0.189x | -113.45% |
| 2007-12-31 | $53.05 Million | $74.48 Million | 1.404x | +147.72% |
| 2006-12-31 | $5.90 Million | $-17.36 Million | -2.942x | -387.56% |
| 2005-12-31 | $-7.58 Million | $-7.75 Million | 1.023x | -- |
About Enovis Corp
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compres… Read more